151 related articles for article (PubMed ID: 32797212)
21. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
[TBL] [Abstract][Full Text] [Related]
22. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
23. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract][Full Text] [Related]
24. Multilevel Small Area Estimation of Prostate-Specific Antigen Screening Test in the United States by Age Group: 2018 Behavioral Risk Factor Surveillance System.
Berkowitz Z; Zhang X; Richards TB; Sabatino SA; Peipins LA; Smith JL
J Am Board Fam Med; 2021; 34(3):634-647. PubMed ID: 34088823
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation.
Howard DH; Tangka FK; Guy GP; Ekwueme DU; Lipscomb J
Health Aff (Millwood); 2013 Mar; 32(3):596-602. PubMed ID: 23459740
[TBL] [Abstract][Full Text] [Related]
26. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
27. The politics of prostate cancer screening.
Kaffenberger SD; Penson DF
Urol Clin North Am; 2014 May; 41(2):249-55. PubMed ID: 24725487
[TBL] [Abstract][Full Text] [Related]
28. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
[TBL] [Abstract][Full Text] [Related]
29. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
[TBL] [Abstract][Full Text] [Related]
30. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
Li J; Berkowitz Z; Hall IJ
J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
[TBL] [Abstract][Full Text] [Related]
31. Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.
Presti J; Alexeeff S; Horton B; Prausnitz S; Avins AL
J Gen Intern Med; 2020 May; 35(5):1368-1374. PubMed ID: 31820217
[TBL] [Abstract][Full Text] [Related]
32. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
33. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
34. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.
Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Thompson RH; Han LC; Shah ND; Smaldone MC; Gross CP; Frank I; Weight CJ; Beebe TJ; Tilburt JC
BJU Int; 2014 May; 113(5b):E106-11. PubMed ID: 24053213
[TBL] [Abstract][Full Text] [Related]
35. National evidence on the use of shared decision making in prostate-specific antigen screening.
Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
[TBL] [Abstract][Full Text] [Related]
36. PSA screening among elderly men with limited life expectancies.
Walter LC; Bertenthal D; Lindquist K; Konety BR
JAMA; 2006 Nov; 296(19):2336-42. PubMed ID: 17105796
[TBL] [Abstract][Full Text] [Related]
37. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
39. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
[TBL] [Abstract][Full Text] [Related]
40. Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline.
Jiang C; Fedewa SA; Wen Y; Jemal A; Han X
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):77-80. PubMed ID: 32296126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
